All In Biotech

Drug Trial Radar · NCT05102136

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN9933, a Monoclonal Antibody Against Factor XI, in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Oct 27, 2021

Primary completion

Apr 4, 2023

Study completion Apr 4, 2023

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety and tolerability of single doses of REGN9933 in healthy participants The secondary objectives of the study are to: * Evaluate the effects of single doses of REGN9933 on intrinsic/common pathway coagulation * Evaluate the effects of single doses of REGN9933 on extrinsic/common pathway coagulation * Characterize the drug concentration profiles and pharmacokinetic (PK) following single escalating doses of REGN9933 * Characterize the concentration profiles of total FXI following single escalating doses of REGN9933 * Assess the immunogenicity of single doses of REGN9933

Conditions

  • Healthy Volunteers

Interventions

  • REGN9933Drug

    Administered intravenously (IV) or subcutaneous (SC) per the protocol

  • PlaceboDrug

    Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment emergent adverse events (TEAE)Time frame: Until resolution of pharmacodynamic (PD) effects; approximately 36 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Regeneron Study Site

    Edegem, Antwerp, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.